Search: onr:"swepub:oai:DiVA.org:uu-305498" >
-
Hjorth-Hansen, H.St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway.,St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway
(author)
Safety and efficacy of the combination of pegylated interferon-alpha 2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients
- Article/chapterEnglish2016
Publisher, publication year, extent ...
-
2016-05-02
-
Springer Science and Business Media LLC,2016
-
printrdacarrier
Numbers
-
LIBRIS-ID:oai:DiVA.org:uu-305498
-
https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-305498URI
-
https://doi.org/10.1038/leu.2016.121DOI
-
https://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-132071URI
Supplementary language notes
-
Language:English
-
Summary in:English
Part of subdatabase
Classification
-
Subject category:ref swepub-contenttype
-
Subject category:art swepub-publicationtype
Notes
-
Funding Agencies|Bristol-Myers Squibb; Norwegian University of Science and Technology (NTNU, Trondheim, Norway)
-
Dasatinib (DAS) and interferon-a have antileukemic and immunostimulatory effects and induce deep responses in chronic myeloid leukemia (CML). We assigned 40 newly diagnosed chronic-phase CML patients to receive DAS 100 mg o.d. followed by addition of pegylated interferon-alpha 2b (PegIFN) after 3 months (M3). The starting dose of PegIFN was 15 mu g/week and it increased to 25 mu g/week at M6 until M15. The combination was well tolerated with manageable toxicity. Of the patients, 84% remained on PegIFN at M12 and 91% (DAS) and 73% (PegIFN) of assigned dose was given. Only one patient had a pleural effusion during first year, and three more during the second year. After introduction of PegIFN we observed a steep increase in response rates. Major molecular response was achieved in 10%, 57%, 84% and 89% of patients at M3, M6, M12 and M18, respectively. At M12, MR4 was achieved by 46% and MR4.5 by 27% of patients. No patients progressed to advanced phase. In conclusion, the combination treatment appeared safe with very promising efficacy. A randomized comparison of DAS +/- PegIFN is warranted.
Subject headings and genre
Added entries (persons, corporate bodies, meetings, titles ...)
-
Stentoft, J.Aarhus Univ Hosp, Dept Hematol, Aarhus, Denmark.,Aarhus University Hospital, Denmark
(author)
-
Richter, J.Skane Univ Hosp, Dept Hematol & Vasc Disorders, Lund, Sweden.,Skåne University Hospital, Sweden
(author)
-
Koskenvesa, P.Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.,University of Helsinki, Finland; Helsinki University Hospital, Sweden
(author)
-
Höglund, MartinUppsala universitet,Hematologi,University of Uppsala Hospital, Sweden(Swepub:uu)martinhl
(author)
-
Dreimane, ArtaLinköpings universitet,Institutionen för klinisk och experimentell medicin,Hälsouniversitetet,Region Östergötland, Hematologiska kliniken US(Swepub:liu)artdr13
(author)
-
Porkka, K.Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.
(author)
-
Gedde-Dahl, T.Oslo Univ Hosp, Rikshosp, Dept Hematol, Oslo, Norway.,Oslo University Hospital, Norway
(author)
-
Gjertsen, B. T.Haukeland Hosp, Hematol Sect, Dept Internal Med, Bergen, Norway.;Univ Bergen, Dept Clin Sci, Bergen, Norway.,Haukeland Hospital, Norway; University of Bergen, Norway
(author)
-
Gruber, F. X.Univ Hosp North Norway, Dept Hematol, Tromso, Norway.,University Hospital North Norway, Norway
(author)
-
Stenke, L.Karolinska Univ Hosp, Dept Hematol, Stockholm, Sweden.;Karolinska Inst, Stockholm, Sweden.,Karolinska University Hospital, Sweden; Karolinska Institute, Sweden
(author)
-
Eriksson, K. M.Sunderbysjukhuset, Dept Internal Med, Lulea, Sweden.
(author)
-
Markevarn, B.Umea Univ Hosp, Dept Hematol, Umea, Sweden.,Umeå University Hospital, Sweden
(author)
-
Lubking, A.Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.,University of Helsinki, Finland; Helsinki University Hospital, Sweden
(author)
-
Vestergaard, H.Odense Univ Hosp, Dept Hematol, Odense, Denmark.,Odense University Hospital, Denmark
(author)
-
Udby, L.Roskilde Hosp, Dept Hematol, Roskilde, Denmark.,Roskilde Hospital, Denmark
(author)
-
Bjerrum, O. W.Univ Copenhagen Hosp, Dept Hematol, Rigshosp, Copenhagen, Denmark.,University of Copenhagen Hospital, Denmark
(author)
-
Persson, IngerUppsala universitet,Statistiska institutionen,Uppsala University, Sweden(Swepub:uu)ingperss
(author)
-
Mustjoki, S.Univ Helsinki, Hematol Res Unit Helsinki, Helsinki, Finland.;Helsinki Univ Hosp, Ctr Comprehens Canc, Dept Hematol, Helsinki, Sweden.;Univ Helsinki, Dept Clin Chem, Helsinki, Finland.,University of Helsinki, Finland; Helsinki University Hospital, Sweden; University of Helsinki, Finland
(author)
-
Olsson-Strömberg, UllaUppsala universitet,Hematologi,University of Uppsala Hospital, Sweden(Swepub:uu)ulols170
(author)
-
St Olavs Hosp, Dept Hematol, PB 8250 Sluppen, NO-7006 Trondheim, Norway.;Norwegian Univ Sci & Technol NTNU, Dept Canc Res & Mol Med, Trondheim, Norway.St Olavs Hospital, Norway; Norwegian University of Science and Technology NTNU, Norway
(creator_code:org_t)
Related titles
-
In:Leukemia: Springer Science and Business Media LLC30:9, s. 1853-18600887-69241476-5551
Internet link
To the university's database
- By the author/editor
-
Hjorth-Hansen, H ...
-
Stentoft, J.
-
Richter, J.
-
Koskenvesa, P.
-
Höglund, Martin
-
Dreimane, Arta
-
show more...
-
Porkka, K.
-
Gedde-Dahl, T.
-
Gjertsen, B. T.
-
Gruber, F. X.
-
Stenke, L.
-
Eriksson, K. M.
-
Markevarn, B.
-
Lubking, A.
-
Vestergaard, H.
-
Udby, L.
-
Bjerrum, O. W.
-
Persson, Inger
-
Mustjoki, S.
-
Olsson-Strömberg ...
-
show less...
- About the subject
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Cancer and Oncol ...
-
- MEDICAL AND HEALTH SCIENCES
-
MEDICAL AND HEAL ...
-
and Clinical Medicin ...
-
and Hematology
- Articles in the publication
-
Leukemia
- By the university
-
Uppsala University
-
Linköping University